HCAI/II-IN-6

HCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and > 50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy[1].

Product Specifications

CAS Number

[694466-00-7]

UNSPSC

12352005

Hazard Statement

H302-H315-H319

Target

Carbonic Anhydrase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/hcai-ii-in-6.html

Purity

98.0

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(S(=O)(N)=O)C=C1)CN2CCN(CC3=CC=CC=C3)CC2

Molecular Formula

C19H24N4O3S

Molecular Weight

388.48

Precautions

P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Mishra CB, et al. Discovery of Benzenesulfonamides with Potent Human Carbonic Anhydrase Inhibitory and Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Assessment. J Med Chem. 2017 Mar 23;60 (6) :2456-2469.